For most older adults, a beta-3 agonist such as mirabegron (Myrbetriq) or vibegron (Gemtesa) is the preferred medication for overactive bladder. These drugs relax the bladder muscle to reduce urgency and frequency without the cognitive side effects that make older anticholinergic medications risky for seniors. The choice matters more in this age group than any other, because the most commonly prescribed OAB drugs can meaningfully increase the risk of confusion and dementia with long-term use.
Why Beta-3 Agonists Are Preferred for Seniors
Two broad classes of medication treat overactive bladder: antimuscarinics (also called anticholinergics) and beta-3 agonists. Both work, but they carry very different risks for older adults. A white paper from the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction advises that when medication is needed for OAB, a beta-3 agonist is typically preferred before trying an antimuscarinic. The American Urological Association’s current guidelines emphasize that OAB medications are equally effective regardless of age, so the deciding factor for seniors is safety, not potency.
Mirabegron and vibegron are the two beta-3 agonists currently available. In a randomized trial of 131 women aged 70 and older, both drugs showed comparable improvement in OAB symptoms over 12 weeks, with no statistically significant difference between them. Side effects were mild in both groups, mostly dry mouth and constipation. Serious adverse events were rare and unrelated to either drug.
The Cognitive Risk of Anticholinergics
Anticholinergic OAB drugs include oxybutynin (Ditropan), tolterodine (Detrol), solifenacin (Vesicare), darifenacin (Enablex), fesoterodine (Toviaz), and trospium (Sanctura). All of these carry the highest possible score on the Anticholinergic Cognitive Burden Scale, meaning they have a definite impact on brain function. Each drug at that burden level may increase the risk of cognitive impairment by 46% over six years of use. The AUA/SUFU guidelines note that chronic use of antimuscarinics beyond three months is likely associated with increased risk of new-onset dementia.
The AGS Beers Criteria, a widely used safety reference for prescribing to older adults, lists all oral antimuscarinic bladder drugs as medications to avoid in seniors with delirium, dementia, cognitive impairment, or chronic constipation. The evidence linking these drugs to worsening delirium is rated as moderate quality, and the recommendation to avoid them in that population is strong. For constipation, the concern is that antimuscarinics slow gut motility, a problem already common in older adults.
This doesn’t mean anticholinergics are never appropriate for a senior. If beta-3 agonists don’t provide enough relief or aren’t tolerated, an antimuscarinic may still be worth trying. But the cognitive risks should be part of the conversation, especially for anyone already showing signs of memory problems.
Mirabegron vs. Vibegron: How They Compare
Both beta-3 agonists work through the same mechanism and produce similar results. The practical differences come down to dosing, drug interactions, and individual response.
Mirabegron starts at 25 mg once daily and can be increased to 50 mg based on how well it works and how well you tolerate it. No dose adjustment is needed for age alone. However, if kidney function is significantly reduced, the dose should stay at 25 mg. The same applies to moderate liver impairment. Mirabegron can interact with digoxin, a heart medication common in older adults, and with metoprolol, a widely used beta-blocker. If you or your family member takes either of these, the prescribing doctor may need to adjust doses.
Vibegron is taken at a flat 75 mg dose once daily. It has fewer known drug interactions than mirabegron, which can be an advantage for seniors taking multiple medications. In the head-to-head trial of elderly women, vibegron had a numerically higher rate of treatment-related side effects (32% vs. 22%), but the difference was not statistically significant, and most side effects were mild.
How Long Before Symptoms Improve
OAB medications don’t work overnight. Mirabegron is considered effective within eight weeks at the starting dose. Symptom improvement generally unfolds over weeks to months rather than days, so it’s important not to abandon a medication too quickly. Keeping a bladder diary, where you record how often you urinate, how many leakage episodes you have, and how strong the urgency feels, can help you and your doctor track whether the medication is making a real difference. Small improvements that are hard to notice day-to-day often become clear when you compare a week’s worth of data from before and after starting treatment.
When Medication Isn’t the Right Fit
Current guidelines no longer require patients to follow a strict step-by-step progression from behavioral therapy to medication to procedures. Instead, the emphasis is on shared decision-making. Some older adults may prefer to start with non-drug approaches, or to combine them with medication from the beginning.
Behavioral strategies like timed voiding (going to the bathroom on a schedule rather than waiting for urgency), pelvic floor exercises, and fluid management can reduce symptoms meaningfully on their own. These carry no side effects and can be used alongside any medication.
For seniors who can’t tolerate medications or don’t get enough relief from them, percutaneous tibial nerve stimulation (PTNS) is a non-invasive, office-based option. It involves a thin needle placed near the ankle that sends gentle electrical pulses to the nerves controlling the bladder. In one study, 86% of patients reported symptom improvement. Daytime bathroom trips dropped by about 25%, nighttime trips fell by 47%, and incontinence episodes decreased by nearly 80%. The treatment requires weekly office visits for an initial course, then periodic maintenance sessions.
Choosing the Right Approach
The “best” medication depends on the individual. For most older adults, the starting point is a beta-3 agonist, with the specific choice influenced by what other medications they take and how their kidneys and liver are functioning. Someone on digoxin or metoprolol might do better with vibegron to avoid interactions. Someone with reduced kidney function would start mirabegron at the lower dose and stay there.
What matters most is avoiding the trap of defaulting to older anticholinergic drugs simply because they’ve been around longer. The cognitive risks are real and cumulative. A 75-year-old who starts oxybutynin and stays on it for years faces a substantially higher chance of developing dementia than one who uses a beta-3 agonist or a non-drug approach. For an older adult already managing multiple health conditions, that risk is worth taking seriously when safer alternatives exist.